AU5207399A - Efflux pump inhibitors - Google Patents
Efflux pump inhibitorsInfo
- Publication number
- AU5207399A AU5207399A AU52073/99A AU5207399A AU5207399A AU 5207399 A AU5207399 A AU 5207399A AU 52073/99 A AU52073/99 A AU 52073/99A AU 5207399 A AU5207399 A AU 5207399A AU 5207399 A AU5207399 A AU 5207399A
- Authority
- AU
- Australia
- Prior art keywords
- pump inhibitors
- efflux pump
- efflux
- inhibitors
- pump
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/108,906 US6399629B1 (en) | 1998-06-01 | 1998-07-01 | Efflux pump inhibitors |
US09108906 | 1998-07-01 | ||
PCT/US1999/014871 WO2000001714A1 (en) | 1998-07-01 | 1999-06-29 | Efflux pump inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5207399A true AU5207399A (en) | 2000-01-24 |
Family
ID=22324746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU52073/99A Abandoned AU5207399A (en) | 1998-07-01 | 1999-06-29 | Efflux pump inhibitors |
Country Status (3)
Country | Link |
---|---|
US (1) | US6399629B1 (US06399629-20020604-C00163.png) |
AU (1) | AU5207399A (US06399629-20020604-C00163.png) |
WO (1) | WO2000001714A1 (US06399629-20020604-C00163.png) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346391B1 (en) | 1999-07-22 | 2002-02-12 | Trustees Of Tufts College | Methods of reducing microbial resistance to drugs |
EP1226138B1 (en) | 1999-10-08 | 2004-12-29 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
WO2002014271A1 (fr) * | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
US6809093B2 (en) | 2000-10-17 | 2004-10-26 | H. Lee Moffitt Cancer & Research Institute, Inc. | 2-substituted heterocyclic compounds |
EP1372674B1 (en) * | 2001-03-08 | 2011-05-25 | The Trustees of The University of Pennsylvania | Facially amphiphilic polymers as anti-infective agents |
WO2003088897A2 (en) * | 2001-04-06 | 2003-10-30 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
DE10129510A1 (de) * | 2001-06-19 | 2003-01-23 | Bayer Ag | Verfahren zur Herstellung von chiralen Aminosäurederivaten |
WO2003041483A2 (en) * | 2001-09-18 | 2003-05-22 | Dartmouth College | Method to study and mechanisms of biofilm-related antibiotic resistance |
US20030073945A1 (en) * | 2001-10-17 | 2003-04-17 | Liang-Kuang Diang | Ozone hemodiafiltration device |
JP2006511475A (ja) * | 2002-09-18 | 2006-04-06 | トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 脈絡膜新生血管症の抑制方法 |
ATE443048T1 (de) | 2002-11-20 | 2009-10-15 | Japan Tobacco Inc | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
ES2518316T3 (es) | 2002-12-06 | 2014-11-05 | Debiopharm International Sa | Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia |
WO2004062674A2 (en) | 2003-01-07 | 2004-07-29 | Paratek Pharmaceuticals, Inc. | Substituted polyamines as inhibitors of bacterial efflux pumps |
JP4880448B2 (ja) * | 2003-03-17 | 2012-02-22 | アフィナム ファーマシューティカルズ,インコーポレーテッド | 複数の抗生物質を含む組成物、及びそれを用いる方法 |
CN102432511B (zh) * | 2003-03-17 | 2016-06-08 | 宾夕法尼亚州大学理事会 | 表面两亲聚合物和低聚物及其应用 |
US7585517B2 (en) * | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
CN1922133A (zh) * | 2004-01-23 | 2007-02-28 | 宾夕法尼亚州大学理事会 | 表面两亲性聚芳基和聚芳基炔基聚合物和低聚物及其用途 |
EP1732527A2 (en) * | 2004-03-17 | 2006-12-20 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
AU2005245962A1 (en) * | 2004-05-21 | 2005-12-01 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
US7879795B2 (en) | 2004-05-21 | 2011-02-01 | Mpex Pharmaceuticals, Inc. | Enhancement of tigecycline potency using efflux pump inhibitors |
CA2568914C (en) | 2004-06-04 | 2013-09-24 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
US7696210B2 (en) * | 2004-06-17 | 2010-04-13 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
NZ552093A (en) * | 2004-06-17 | 2009-06-26 | Wyeth Corp | Processes for preparing gonadotropin releasing hormone receptor antagonists |
US20060025468A1 (en) * | 2004-07-29 | 2006-02-02 | Whitten Jeffrey P | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof |
JP2008520732A (ja) * | 2004-11-23 | 2008-06-19 | ワイス | ゴナドトロピン放出ホルモン受容体アンタゴニスト |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
SI1848431T1 (sl) * | 2005-02-09 | 2016-05-31 | Santen Pharmaceutical Co., Ltd. | Tekoče formulacije za zdravljenje bolezni ali stanj |
US7538113B2 (en) * | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US7582634B2 (en) * | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US7534796B2 (en) * | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
US20060241052A1 (en) * | 2005-02-25 | 2006-10-26 | Degrado William F | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
US7582636B2 (en) * | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
JP2009518399A (ja) * | 2005-12-05 | 2009-05-07 | アフィニウム ファーマシューティカルズ, インク. | Fabi阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物 |
WO2007070600A2 (en) * | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(5-membered heteroaromatic ring)-amido anti-viral compounds |
WO2007078990A2 (en) * | 2005-12-23 | 2007-07-12 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
JP5528708B2 (ja) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
US9155792B2 (en) | 2006-02-13 | 2015-10-13 | Trustees Of Boston University | RecA inhibitors with antibiotic activity, compositions and methods of use |
US8383819B2 (en) | 2006-03-06 | 2013-02-26 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
US8222271B2 (en) * | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US8318720B2 (en) * | 2006-07-20 | 2012-11-27 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as Fab I inhibitors |
US20100234348A1 (en) * | 2006-08-04 | 2010-09-16 | Trustees Of Boston University | Compositions and methods for potentiating antibiotic activity |
WO2008098374A1 (en) | 2007-02-16 | 2008-08-21 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab i inhibitors |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
US8178490B2 (en) * | 2007-05-11 | 2012-05-15 | Rempex Pharmaceuticals, Inc. | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof |
EP2155775A2 (en) * | 2007-05-11 | 2010-02-24 | Mpex Pharmaceuticals, Inc. | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof |
MX356695B (es) | 2012-06-19 | 2018-06-11 | Debiopharm Int Sa | Profarmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)me til)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il) acrilamida. |
SG11201502369XA (en) | 2012-10-16 | 2015-05-28 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
KR20150070348A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제 |
AU2013331505A1 (en) | 2012-10-16 | 2015-04-30 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ROR-gamma-t |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
JP6423423B2 (ja) | 2013-10-15 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Rorγtのアルキル結合キノリニルモジュレーター |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
EP3967312A1 (en) | 2014-09-12 | 2022-03-16 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
WO2016159049A1 (ja) * | 2015-03-31 | 2016-10-06 | 武田薬品工業株式会社 | 単環式化合物 |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
US10464896B2 (en) | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
CA2990668A1 (en) | 2015-06-24 | 2016-12-29 | Wenbin Ying | Ionizable compounds and compositions and uses therefof |
WO2017093157A1 (en) | 2015-11-30 | 2017-06-08 | Basilea Pharmaceutica Ag | Piperidine, pyrrolidine and 2-oxo-1,3-oxazinane derivatives as inhibitors of bacterial efflux-pumps for the treatment of microbial infections |
TN2018000293A1 (en) | 2016-02-26 | 2020-01-16 | Debiopharm Int Sa | Medicament for treatment of diabetic foot infections |
CN106397395B (zh) * | 2016-08-31 | 2018-09-04 | 帕潘纳(北京)科技有限公司 | 一种制备2,4-二甲基四氢噻吩-3-酮的方法 |
DK3618847T3 (da) | 2017-05-05 | 2021-05-25 | Boston Medical Ct Corp | GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom |
US11129386B2 (en) * | 2017-09-13 | 2021-09-28 | Syngenta Participations Ag | Microbiocidal quinoline (thio)carboxamide derivatives |
WO2020176067A1 (en) | 2019-02-25 | 2020-09-03 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420297A (en) | 1990-10-24 | 1995-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having substance P antagonistic activity |
CA2155448A1 (en) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibitors of farnesyl protein transferase |
US5989832A (en) * | 1995-04-21 | 1999-11-23 | Microcide Pharmaceuticals, Inc. | Method for screening for non-tetracycline efflux pump inhibitors |
JP4024309B2 (ja) | 1996-10-22 | 2007-12-19 | 第一三共株式会社 | 新規な感染症治療薬 |
-
1998
- 1998-07-01 US US09/108,906 patent/US6399629B1/en not_active Expired - Lifetime
-
1999
- 1999-06-29 AU AU52073/99A patent/AU5207399A/en not_active Abandoned
- 1999-06-29 WO PCT/US1999/014871 patent/WO2000001714A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US6399629B1 (en) | 2002-06-04 |
WO2000001714A1 (en) | 2000-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5207399A (en) | Efflux pump inhibitors | |
AU5713496A (en) | Efflux pump inhibitors | |
AU2337599A (en) | Efflux pump inhibitors | |
AU5136999A (en) | Fluid pump | |
AU4436699A (en) | Fluid well pump | |
AU2361001A (en) | Thick matter pump | |
AU2001245618A1 (en) | Pump actuated sealing system | |
AU2723099A (en) | Tryptase inhibitors | |
AU3235100A (en) | Prothease inhibitors | |
EP1146231A3 (de) | Pumpenaggregat | |
AU2131100A (en) | Piston | |
AU9785698A (en) | Fungal efflux pump inhibitors | |
AU6236199A (en) | Double-acting pump | |
AU3987399A (en) | Injector pump | |
AU2001264445A1 (en) | Reverse-running pump | |
AU2001264350A1 (en) | Multi-scroll pump | |
EP1323926A3 (de) | Pumpe | |
AU2002223457A1 (en) | Pump | |
AUPQ489799A0 (en) | Improved fluid compressor | |
AU5750499A (en) | Electromagnetic pump | |
AU1265299A (en) | Pump | |
EP1144867A3 (de) | Pumpe | |
AU3953899A (en) | Cyclooxygenase-2 inhibitors | |
EP1274932B8 (de) | Pumpe | |
AU2001260058A1 (en) | Pump |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |